Customized Patient Education Materials

Select patient education material(s) to customize and either print or e-mail to your allergy patients by selecting desired check boxes below. To view the patient education material(s) prior to customizing, click on the title(s). After selecting your patient education material(s) below, click the Next Step button to begin customizing the document(s).

	How to Use RHINOCORT AQUA This brochure provides patients easy, step-by-step instructions for using RHINOCORT AQUA.
	Drugs and Pregnancy This piece helps educate your patients about medication use in pregnancy. It describes the FDA safety classifications and emphasizes the importance of discussing all medications with your patients, prior to use, including prescription medicines, over-the-counter medicines, and herbal supplements.
	Nasal Allergies and Pregnancy This brochure provides your patients with information about nasal allergies during pregnancy, including a description of common symptoms, an explanation of why nasal allergies may worsen during pregnancy and what can be done about them.
	Nasal Allergy Tip Sheet This piece gives your patients tips on how to deal with both indoor and outdoor nasal allergies.
	Cold vs Allergy Since colds and nasal allergies display many of the same symptoms, this tool helps patients distinguish whether their symptoms are more indicative of a cold or a nasal allergy.
	Rhinocort Aqua Pollen Counter

Next Step: Customized Allergy Patient Education Materials

Indication and Important Safety Information

RHINOCORT AQUA is indicated for the management of nasal symptoms of seasonal or perennial allergic rhinitis in adults and children 6 years of age and older.

Maximum benefit may not be achieved until approximately 2 weeks after initiation of treatment. Effectiveness depends on regular use.

The replacement of systemic corticosteroid with a topical corticosteroid may be accompanied by signs of adrenal insufficiency, and some patients may experience symptoms of withdrawal such as joint and/or muscular pain, lassitude and depression.

Experience with RHINOCORT AQUA in pregnant women has not shown an increased risk of fetal abnormalities. Despite adverse events in animals reproductive studies, it would appear that the possibility of human fetal harm is remote. See PRECAUTIONS in full Prescribing Information. RHINCORT AQUA should be used in pregnancy only if clearly needed.

It is not known whether budesonide is excreted in human milk. Because other corticosteroids are excreted in human milk, caution should be exercised when RHINOCORT AQUA Nasal Spray is administered to nursing women.

The recommended starting dosage of RHINOCORT AQUA is 1 spray per nostril once daily (64 mcg total daily dose), with individualized dosing up to 256 mcg for adults (12 years of age and older) and 128 mcg for children aged 6 to 11 years. Prescribe the lowest amount necessary for control of symptoms.

The overall incidence of adverse events with RHINOCORT AQUA was similar to that observed with placebo vehicle. In clinical trials, commonly reported adverse events with RHINOCORT AQUA versus placebo vehicle were epistaxis (8% vs 5%), pharyngitis (4% vs 3%), bronchospasm (2% vs 1%), coughing (2% vs <1%), and nasal irritation (2% vs <1%).

Please click here for full Prescribing Information

Legal Information

RHINOCORT AQUA is a registered trademark of the AstraZeneca group of companies.

This product information is intended for US Health Care Professionals only.